Mouse models of 22q11 deletion syndrome

被引:52
作者
Paylor, Richard
Lindsay, Elizabeth
机构
[1] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/j.biopsych.2006.01.018
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
22q11 deletion syndrome (22q11DS) is caused by an interstitial chromosomal microdeletion that encompasses about 40 genes. It is the most common of the microdeletion syndromes. The clinical phenotype, which is complex and variable, includes specific congenital defects of the cardiovascular system, craniofacies, and immune system. In early childhood, patients manifest cognitive impairment, behavioral disorders, and delays in motor development and language acquisition. Adult patients have a high Fisk for developing serious psychiatric disorders, especially schizophrenia, schizoaffective disorder, and bipolar disorder. The great majority of patients have an identical or near identical chromosomal deletion, and genotype-phenotype correlations have not been established. indeed, little progress was made toward resolving the complex clinical phenotype until the deletion was successfully modeled in the mouse. In recent years, through a variety of mouse mutants that carry multigene and single gene mutations, we have learned that mutation in a single gene, Tbx1, is responsible for most of the congenital defects seen in the mouse models and inpatients. We now face a greater challenge as we attempt to use the mouse to address the pathogenesis of the behavioral and psychiatric disorders associated with 22q11DS. Significant progress has already been made, and recent studies in the mouse suggest that several genes from the deleted region affect behavior and might contribute to disease burden in patients.
引用
收藏
页码:1172 / 1179
页数:8
相关论文
共 87 条
  • [1] Abou Jamra R, 2005, PSYCHIAT GENET, V15, P195
  • [2] Velo-cardio-facial syndrome: Implications of microdeletion 22q11 for schizophrenia and mood disorders
    Arnold, PD
    Siegel-Bartelt, J
    Cytrynbaum, C
    Teshima, I
    Schachar, R
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 2001, 105 (04): : 354 - 362
  • [3] Bassett AS, 1998, AM J MED GENET, V81, P328, DOI 10.1002/(SICI)1096-8628(19980710)81:4<328::AID-AJMG10>3.3.CO
  • [4] 2-8
  • [5] The schizophrenia phenotype in 22q11 deletion syndrome
    Bassett, AS
    Chow, EWC
    AbdelMalik, P
    Gheorghiu, M
    Husted, J
    Weksberg, R
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (09) : 1580 - 1586
  • [6] Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome
    Bearden, CE
    Jawad, AF
    Lynch, DR
    Sokol, S
    Kanes, SJ
    McDonald-McGinn, DM
    Saitta, SC
    Harris, SE
    Moss, E
    Wang, PP
    Zackai, E
    Emanuel, BS
    Simon, TJ
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (09) : 1700 - 1702
  • [7] A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population
    Botto, LD
    May, K
    Fernhoff, PM
    Correa, A
    Coleman, K
    Rasmussen, SA
    Merritt, RK
    O'Leary, LA
    Wong, LY
    Elixson, EM
    Mahle, WT
    Campbell, RM
    [J]. PEDIATRICS, 2003, 112 (01) : 101 - 107
  • [8] PRE-STIMULUS EFFECTS ON HUMAN STARTLE REFLEX IN NORMALS AND SCHIZOPHRENICS
    BRAFF, D
    STONE, C
    CALLAWAY, E
    GEYER, M
    GLICK, I
    BALI, L
    [J]. PSYCHOPHYSIOLOGY, 1978, 15 (04) : 339 - 343
  • [9] BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181
  • [10] Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
    Braff, DL
    Geyer, MA
    Swerdlow, NR
    [J]. PSYCHOPHARMACOLOGY, 2001, 156 (2-3) : 234 - 258